[ad_1]
OSLO, Norway, Aug 20, 2021 (GLOBE NEWSWIRE) – Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical leader in immunostimulatory cancer vaccines, today announced its second quarter 2021 results. The Company’s management team will be webcast today at 9:00 am CEST.
The presentation can be followed as a live webcast (access via the link https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20210820_5) which will also be available on our website.
Highlights of the second quarter of 2021:
- Data from cohort 1 of the phase I clinical trial of UV1 with pembrolizumab were presented in June at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO). The primary endpoint of safety and tolerability was met with strong initial signs of clinical response.
- The results of 10 patients in cohort 2 of the same trial published on August 12 also showed strong safety and efficacy data after one year (60% objective response, 30% complete response, 90% overall survival and median progression-free survival not achieved), reinforcing the data from cohort 1 presented to ASCO.
- INITIUM trial: 68 patients included to date against 40 patients in the previous quarterly report.
- NIPU trial: 38 patients recruited to date against 29 patients in the previous quarterly report.
- FOCUS trial: The first patient was recruited on August 4, 2021.
- DOVACC trial: Regulatory approval is in place and the first patient is expected to be enrolled in the third quarter of 2021.
- TRENDS trial: The recruitment of the first cohort of three patients treated with a dose of 40 µg has been completed. In June 2021, having found no safety concerns in the first cohort, the Drug Safety Monitoring Board authorized the increase in the dose to 400 μg for the next patient in cohort 2.
- COVID-19: The effect of the pandemic on the biotech industry and the general ability to conduct clinical trials is still uncertain and depends on the speed of return to a more normal situation. The Company continues to monitor the situation and implement activities to minimize the impact on patient recruitment.
- Total operating expenses amount to MNOK 39.2 at T2-21, and MNOK 70.4 YTD.
- Cash flow from operations was MNOK -29.8 at T2-21, and MNOK -59.2 YTD. Total cash and cash equivalents has been reduced by MNOK 29.7 during Q2-21 and amounted to MNOK 381.8 as of June 30, 2021.
The report and presentation are also available on the Company’s website:
www.ultimovacs.com/investors/reports-and-presentations
For more information, visit www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: [email protected]
Telephone: +47 908 92507
Hans Vassgård Eid, Chief Financial Officer
Email: [email protected]
Telephone: +47 482 48632
Mary-Ann Chang, LifeSci Advisors
Email: [email protected]
Telephone: +44 7483 284 853
This information is considered inside information in accordance with the EU Market Abuse Regulation and is subject to disclosure requirements in accordance with Section 5-12 of the Norwegian Securities Act.
This stock market announcement was posted by Hans Vassgård Eid, CFO at Ultimovacs ASA, on August 20, 2021 at 08:00 CET.
Source link
